DURECT Corporation Announces Presentations in Upcoming Investor Conferences
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update....
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the...